Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?

Amarin's (NASDAQ: AMRN) shares rocketed higher after a key FDA committee recommended expanding the label of its triglyceride-lowering drug, Vascepa, to include data showing it can reduce the risk of heart attack and stroke. Meanwhile, shares in CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals (NASDAQ: VRTX) are also soaring following the release of interim, early-stage results for its gene-editing therapy for beta thalassemia and sickle cell disease therapy.

To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.

Continue reading

Source Fool.com